Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLCG1 | P19174 | 8/20 | 0.56 |
| ▸ | SRC | P12931 | 1/20 | 0.53 |
| ▸ | GAK | O14976 | 1/20 | 0.53 |
| ▸ | BTK | Q06187 | 5/20 | 0.53 |
| ▸ | ITK | Q08881 | 4/20 | 0.53 |
| ▸ | EGFR | P00533 | 2/20 | 0.52 |
| ▸ | JAK3 | P52333 | 2/20 | 0.49 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30190831 | 1.00 | PLCG1 (0.56) | PLCG1SRCGAKBTKITK | |
| SCHEMBL24150178 | 0.85 | PLCG1 (0.57) | PLCG1SRCBTKITKEGFR | |
| SCHEMBL30190644 | 0.85 | PLCG1 (0.57) | PLCG1SRCBTKITKEGFR | |
| SCHEMBL24150583 | 0.84 | EGFR (0.60) | PLCG1SRCBTKITKEGFR | |
| SCHEMBL24150187 | 0.84 | PLCG1 (0.56) | PLCG1SRCBTKITKEGFR | |
| SCHEMBL30191070 | 0.84 | BTK (0.60) | PLCG1SRCBTKITKEGFR | |
| SCHEMBL24150478 | 0.84 | BTK (0.60) | PLCG1SRCBTKITKEGFR | |
| SCHEMBL30190386 | 0.84 | PLCG1 (0.56) | PLCG1SRCBTKITKEGFR | |
| SCHEMBL24150585 | 0.83 | PLCG1 (0.54) | PLCG1SRCBTKITKEGFR | |
| SCHEMBL24150192 | 0.83 | EGFR (0.59) | PLCG1SRCBTKITKEGFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11926632-B2 | Methods and compounds for restoring mutant p53 function | PMV PHARMACEUTICALS, INC. (US) | 2024-03-12 | — | — | US | disclosed |
| US-20230046427-A1 | METHODS AND COMPOUNDS FOR RESTORING MUTANT p53 FUNCTION | PMV PHARMACEUTICALS, INC. | 2023-02-16 | — | — | US | disclosed |
| US-20230046427-A1 | METHODS AND COMPOUNDS FOR RESTORING MUTANT p53 FUNCTION | PMV PHARMACEUTICALS, INC. | 2023-02-16 | — | — | US | disclosed |
| WO-2021262596-A1 | METHODS AND COMPOUNDS FOR RESTORING MUTANT P53 FUNCTION | PMV PHARMACEUTICALS, INC. (US) | 2021-12-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230046427-A1 | METHODS AND COMPOUNDS FOR RESTORING MUTANT p53 FUNCTION | TP53, TP53BP1, HRAS | PLCG1 2034/4885SRC 666/4885GAK 681/4885 |
| US-11926632-B2 | Methods and compounds for restoring mutant p53 function | TP53, TP53BP1, HRAS | PLCG1 2034/4885SRC 666/4885GAK 681/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.